TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38713024

Group type: EXPERIMENTAL
Intervention: Cascaded deep learning-based algorithm for intraprostatic lesion detection and segmentation.
Number of subjects: 658

Group type: COMPARATOR
Intervention: Radiologist readings.
Number of subjects: 658
Study: 38713047

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with lung damage
Number of subjects: 0
Study: 38713063

Group type: EXPERIMENTAL
Intervention: Self-monitoring with feedback (SM + FB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38713137

Group type: EXPERIMENTAL
Intervention: 4L-PEG+1d-Lin
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 3L-PEG+3d-Lin
Number of subjects: 502

Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 3L-PEG+1d-Lin
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 502
Study: 38713142

Group type: EXPERIMENTAL
Intervention: Heartfulness meditation (HFM)
Number of subjects: 30
Study: 38713205

Group type: EXPERIMENTAL
Intervention: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surufatinib plus toripalimab
Number of subjects: 60
Study: 38713231

Group type: EXPERIMENTAL
Intervention: Prebiotic intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 38713248

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 166
Study: 38713274

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 175

Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 175
Study: 38713475

Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 46
Study: 38713500

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for PVCs, delivered over 10 weeks via videoconference with online text-based information and homework assignments.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for PVCs
Number of subjects: 19
Study: 38713508

Group type: EXPERIMENTAL
Intervention: Device-assisted 6-minute walk test (6MWT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Device-assisted Timed Up and Go test (TUG)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wearable devices (Verily Study Watch and Modus StepWatch)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standardized questionnaires and tests (6MWT and TUG)
Number of subjects: 200
Study: 38713581

Group type: EXPERIMENTAL
Intervention: Classical and nonclassical monocytes, analyzed using single-cell RNA sequencing and pathway analyses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic targets for chronic critical illness risk.
Number of subjects: 0
Study: 38713595

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (CAR T-cell therapy)
Number of subjects: 97
Study: 38713611

Group type: COMPARATOR
Intervention: D2 lymphadenectomy
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy + complete mesogastric excision
Number of subjects: 338
Study: 38713673

Group type: EXPERIMENTAL
Intervention: De novo RECOVER prospective cohort of children and young adults with and without previous or current infection (n = 6000)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up for up to 4 years (Tier 2, n = 6000)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Deep phenotyping subset of participants primarily the most severely affected by PASC (Tier 3, n = 600)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Youth enrolled in the ABCD study (Tier 1)
Number of subjects: 10000
Study: 38713818

Group type: EXPERIMENTAL
Intervention: Infants born in November
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Infants born in October
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Infants meeting specific conditions (born in other months, at term, by vaginal delivery and without siblings)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Other infants
Number of subjects: 555
Study: 38713888

Group type: EXPERIMENTAL
Intervention: Mass spectrometry (MS) assessment of measurable residual disease (MRD) negativity during posttransplant therapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Combined PB/BM MRD negativity by MFC or NGS
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sustained MS negativity
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Posttransplant MS assessment
Number of subjects: 138
Study: 38713894

Group type: EXPERIMENTAL
Intervention: Personalized neoantigen vaccination combined with PD-1 blockade
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Synthetic long peptide vaccines targeting predicted high-quality neoantigens
Number of subjects: 57
Study: 38713909

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-assisted weight management app (eTRIP)
Number of subjects: 0
Study: 38714105

Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP) intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 88
Study: 38714144

Group type: EXPERIMENTAL
Intervention: NSSI participants
Number of subjects: 117
Study: 38714422

Group type: EXPERIMENTAL
Intervention: topical promestriene for 90 days (n=17)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: fractional CO2 laser treatment (n=24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: microablative fractional radiofrequency treatment (n=21)
Number of subjects: 62
Study: 38714459

Group type: EXPERIMENTAL
Intervention: CCTA assessment of total occlusions (TOs)
Number of subjects: 114
Study: 38714557

Group type: EXPERIMENTAL
Intervention: Lowest quartile of age at diabetes diagnosis
Number of subjects: 15773

Group type: COMPARATOR
Intervention: Higher quartiles of age at diabetes diagnosis
Number of subjects: 15773
Study: 38714632

Group type: EXPERIMENTAL
Intervention: Bariatrifast vitamin/mineral formula
Number of subjects: 20
Study: 38714692

Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine regimen
Number of subjects: 303

Group type: COMPARATOR
Intervention: 3-day artemether-lumefantrine regimen
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 303
Study: 38714786

Group type: EXPERIMENTAL
Intervention: THC (10-80 mg, individually dosed)
Number of subjects: 185
Study: 38714898

Group type: EXPERIMENTAL
Intervention: Personalized dietary program (PDP)
Number of subjects: 347

Group type: COMPARATOR
Intervention: General dietary advice (control)
Number of subjects: 347
Study: 38714924

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1% lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38714926

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry directed feeding and 60 min/day of cycle ergometry
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard weight-based empiric feeding and standard ICU physiotherapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 21
Study: 38714940

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 blood pressure measurements
Number of subjects: 5355

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 hypertension status
Number of subjects: 5355

Group type: EXPERIMENTAL
Intervention: Predictive factors for increased BP
Number of subjects: 5355
Study: 38714957

Group type: EXPERIMENTAL
Intervention: Integrated intrinsic foot muscle exercise with a three-dimensional printing foot core training device
Number of subjects: 40
Study: 38714999

Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 38715118

Group type: EXPERIMENTAL
Intervention: LUS-guided personalized mechanical ventilation
Number of subjects: 538

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 538
Study: 38715135

Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercise (TSE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mulligan joint mobilization (MWM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isometric knee strengthening (KSE)
Number of subjects: 60
Study: 38715140

Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation (2 infusions of 100 million cells i.v)
Number of subjects: 12
Study: 38715179

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 591

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 591
Study: 38715621

Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) therapy with bortezomib, rituximab, methotrexate, and intravenous immunoglobulin over 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) therapy
Number of subjects: 8
Study: 38716419

Group type: EXPERIMENTAL
Intervention: Ciprofol (0.4 mg/kg for induction and 0.2 mg/kg for maintenance)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Propofol (2.0 mg/kg for induction and 1.0 mg/kg for maintenance)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135
Study: 38716555

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study: 38716626

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 970

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 970
Study: 38716987

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442
Study: 38717025

Group type: EXPERIMENTAL
Intervention: Microbiome-based artificial intelligence-assisted personalized diet (PD)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-FODMAP diet (FODMAP)
Number of subjects: 121
Study: 38717038

Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon (0.66 mg/kg/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily somatropin (0.24 mg/kg/week)
Number of subjects: 0
Study: 38717075

Group type: EXPERIMENTAL
Intervention: D3S-001, a next-generation GDP-bound G12C inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sotorasib and adagrasib (first-generation KRAS G12C inhibitors)
Number of subjects: 0
Study: 38717237

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 516

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 516
Study: 38717424

Group type: EXPERIMENTAL
Intervention: Intermediate AMD eyes
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Early AMD eyes
Number of subjects: 502

Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Transition from early to intermediate AMD
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Overall structural differences
Number of subjects: 502
Study: 38717556

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No beta blockers
Number of subjects: 0
Study: 38717577

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 175
Study: 38717596

Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Caregivers of adolescents living with obesity (ALwO)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 649
Study: 38717753

Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only strategy
Number of subjects: 1445
Study: 38717762

Group type: EXPERIMENTAL
Intervention: Trauma Medical Home (TMH) intervention for 6 months delivered by a nurse care coordinator guided by an interdisciplinary team.
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study: 38717773

Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP): 1 day of buprenorphine at minimum necessary dose, 1 opioid-free day, ascending low doses of oral naltrexone and adjunctive medications
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard procedure (SP): approximately 5-day buprenorphine taper followed by a 7- to 10-day opioid-free period
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard procedure (SP)
Number of subjects: 415
Study: 38717775

Group type: EXPERIMENTAL
Intervention: Traffic light labels
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Physical activity labels
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Beverage tax posters
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Snack machines
Number of subjects: 1065
Study: 38717812

Group type: EXPERIMENTAL
Intervention: iJobs web-based intervention (2-week duration, 6 modules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 38717861

Group type: EXPERIMENTAL
Intervention: Decitabine (DEC) 10-day schedule
Number of subjects: 606

Group type: COMPARATOR
Intervention: Intensive chemotherapy (IC) 3+7
Number of subjects: 606
Study: 38717915

Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB) patients
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: OAB patients with higher OAB Questionnaire Short-Form scores
Number of subjects: 221
Study: 38717931

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (12-month duration)
Number of subjects: 246
Study: 38717993

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab with chemotherapy
Number of subjects: 0
Study: 38717997

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (three sessions weekly for 8 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Physical activity counselling (control group)
Number of subjects: 98
Study: 38718002

Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) delivered in the ED
Number of subjects: 336

Group type: COMPARATOR
Intervention: No physiotherapy (no-PT group)
Number of subjects: 336
Study: 38718135

Group type: EXPERIMENTAL
Intervention: Autologous polyclonal expanded regulatory T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38718169

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Stress Proofing
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Daily Examen prayer practice
Number of subjects: 255

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 255
Study: 38718190

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 38718358

Group type: EXPERIMENTAL
Intervention: Thrombectomy plus medical care
Number of subjects: 333

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 333
Study: 38718430

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (infraorbital nerve block)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No regional anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 100
Study: 38718683

Group type: EXPERIMENTAL
Intervention: Tamoxifen intake in the evening/nighttime
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) intake
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Overall ET intake timing
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Multivariable analysis of ET intake timing and ET agent
Number of subjects: 1278
Study: 38718786

Group type: EXPERIMENTAL
Intervention: Exhaled breath analysis using secondary electrospray ionization high-resolution mass spectrometry
Number of subjects: 29
Study: 38718923

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) and Artificial Intelligence (AI) model
Number of subjects: 9559
Study: 38718924

Group type: EXPERIMENTAL
Intervention: Total Iodine Intake (TII)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Total Iodine Excretion (TIE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Urinary Iodine Excretion Rate (UIER)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Breast Milk Iodine Excretion Rate (BMIER)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Proportion of iodine excreted in urine and breast milk
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Effect of TII on BMIER when TII <120 μg/d
Number of subjects: 41
Study: 38719277

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (carboplatin and paclitaxel in a 3 weekly scheme) followed by surgery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Primary chemoradiation (tumor dose of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for 6 weeks)
Number of subjects: 98
Study: 38719280

Group type: EXPERIMENTAL
Intervention: Androgenic anabolic steroids (AAS) use
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no previous AAS use)
Number of subjects: 180
Study: 38719313

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg, two capsules two times per day for 7 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (mannitol 312.5 mg), two matching capsules two times per day for 7 days
Number of subjects: 74
Study: 38719320

Group type: EXPERIMENTAL
Intervention: Immediate group (FET performed in the first menstrual cycle following the stimulated IVF cycle)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Delayed group (FET performed at least in the second menstrual cycle following the stimulated IVF cycle)
Number of subjects: 828
Study: 38719321

Group type: EXPERIMENTAL
Intervention: MEDIAL-pivot group
Number of subjects: 99

Group type: COMPARATOR
Intervention: CENTRAL-pivot group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Patient-reported questionnaires
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 6-minute walking test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Timed up-and-go test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Gait analysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Step-over test
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ability to step up and down stairs
Number of subjects: 99
Study: 38719323

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1524
Study: 38719328

Group type: EXPERIMENTAL
Intervention: EvolvRehab telerehabilitation for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EvolvRehab telerehabilitation
Number of subjects: 0
Study: 38719329

Group type: COMPARATOR
Intervention: Bacterial growth assessment in patients with MC1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacterial growth assessment in patients with MC2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment in previously operated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment in patients with large MCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment from the vertebral body in the fusion group
Number of subjects: 0
Study: 38719346

Group type: EXPERIMENTAL
Intervention: Preoperative optical coherence tomography (OCT) morphological features
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Presence of subretinal hyper-reflective points (HRPs)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Presence of foveal detachment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Outer retinal corrugations (ORCs)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intraretinal cystic spaces (ICS)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Foveal involvement
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Subretinal HRPs
Number of subjects: 89
Study: 38719432

Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (iTBS) rTMS to the left dorsolateral prefrontal cortex (8 stimulation sessions of 600 pulses of iTBS/day for 3 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (iTBS) rTMS
Number of subjects: 24
Study: 38719500

Group type: EXPERIMENTAL
Intervention: SERCO model for predicting severe exacerbations
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: SERCO model for predicting COPD-specific readmissions
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: C-index for severe exacerbations
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: C-index for readmissions
Number of subjects: 4065

Group type: COMPARATOR
Intervention: SERCO model vs prior severe exacerbation history
Number of subjects: 4065
Study: 38719544

Group type: EXPERIMENTAL
Intervention: YSCH-01 (Recombinant L-IFN adenovirus)
Number of subjects: 14
Study: 38719803

Group type: EXPERIMENTAL
Intervention: Primaquine (0.25-1 mg base/kg once daily given to the mother for 1-14 days)
Number of subjects: 0
Study: 38719809

Group type: EXPERIMENTAL
Intervention: ATL-DC vaccination + poly-ICLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATL-DC vaccination + resiquimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATL-DC vaccination
Number of subjects: 0
Study: 38720025

Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical training
Number of subjects: 177
Study: 38720113

Group type: EXPERIMENTAL
Intervention: NIPE index for moderate pain
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NIPE index for severe pain
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NIPE index for pain-specific ED-II
Number of subjects: 69

Group type: COMPARATOR
Intervention: NIPE index for emergence delirium
Number of subjects: 69

Group type: COMPARATOR
Intervention: NIPE index for delirium-specific component ED-I
Number of subjects: 69